Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate
(Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients
with hormone-refractory prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center